Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
Website:
http://www.bicara.comNext earnings report:
29 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 04 Oct 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
BCAX Latest News
24/7 Wall St. Insights Initial public offerings at three biotechs last week tempted insiders to make huge purchases of shares.
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the closing of its initial public offering of 20,125,000 shares of its common stock at a public offering price of $18.00 per share, which includes 2,625,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Bicara Therapeutics' shares began trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol “BCAX.” All of the shares of common stock were sold by Bicara Therapeutics.
Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand courier service provider BingEx also filed to raise $100 million. No IPOs are currently scheduled to list in the week ahead, as activity remains somewhat muted in the run-up to the 2024 presidential election.
What type of business is Bicara Therapeutics Common Stock?
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
What sector is Bicara Therapeutics Common Stock in?
Bicara Therapeutics Common Stock is in the Healthcare sector
What industry is Bicara Therapeutics Common Stock in?
Bicara Therapeutics Common Stock is in the Biotechnology industry
What country is Bicara Therapeutics Common Stock from?
Bicara Therapeutics Common Stock is headquartered in United States
What is Bicara Therapeutics Common Stock website?
https://www.bicara.com
Is Bicara Therapeutics Common Stock in the S&P 500?
No, Bicara Therapeutics Common Stock is not included in the S&P 500 index
Is Bicara Therapeutics Common Stock in the NASDAQ 100?
No, Bicara Therapeutics Common Stock is not included in the NASDAQ 100 index
Is Bicara Therapeutics Common Stock in the Dow Jones?
No, Bicara Therapeutics Common Stock is not included in the Dow Jones index
When was Bicara Therapeutics Common Stock the previous earnings report?
No data
When does Bicara Therapeutics Common Stock earnings report?
The next expected earnings date for Bicara Therapeutics Common Stock is 29 November 2024